Alumis Inc. Announces Upsized $259M Series C Financing led by Foresite Capital, Samsara BioCapital and venBio Partners to advance clinical-stage pipeline of oral therapies designed to address immune dysfunction.
Amount Raised
$259 Million
Round Type
Series C
Los AngelesBiotechnologyHealthcareHealth CareInvestors
Description
Alumis Inc. announced an upsized $259M Series C financing led by Foresite Capital, Samsara BioCapital, and venBio Partners. The financing will support ongoing comprehensive mid to late-stage clinical development program for ESK-001 in plaque psoriasis, systemic lupus erythematosus (SLE), and uveitis, as well as the exploration of ESK-001’s potential application in other immune-mediated diseases and the advancement of pipeline programs including A-005 for the treatment of neuroinflammatory and neurodegenerative diseases.
Quick answer
Alumis raised $259 Million in a Series C round, dated March 6, 2024. Investors: Ayur Maya, Piper Heartland Healthcare, Omega Funds, HBM Healthcare Investments, Ally Bridge Group, Nextech, Lilly Asia Ventures and SR One. Alumis is based in Los Angeles, California, United States.
- How much did Alumis raise?
- Alumis raised $259 Million in a Series C round on March 6, 2024.
- Who invested in Alumis?
- Ayur Maya, Piper Heartland Healthcare, Omega Funds, HBM Healthcare Investments, Ally Bridge Group, Nextech, Lilly Asia Ventures and SR One are named as investors in this round.
- What does Alumis do?
- A California-based biotech company specializing in developing oral therapies for immune dysfunction and autoimmune indications, with a focus on TYK2 inhibition.
- Where is Alumis based and how big is it?
- Alumis is based in Los Angeles, California, United States.
- Who are the decision-makers at Alumis?
- Fundz holds 1 contact at Alumis. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Healthcare and Biotechnology around the same time
Companies in the same sectors as Alumis that raised within 45 days of this round, from Fundz verified event records.
- BioLineRx Ltd raised $20M (Pre-Seed) on April 10, 2024.
- Enlaza Therapeutics raised $84M on April 5, 2024.
- Vaccinex raised $1.8M (Seed) on March 29, 2024.
- Vaccinex raised $1.2M (Seed) on March 28, 2024.
- ViaLase raised $38M on March 25, 2024.
- Novabay raised $665K (Seed) on March 24, 2024.
Who to call at Alumis, and when
A new round usually means Alumis is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Alumis raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Alumis, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Alumis. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Alumis raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Alumis raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.